Neoamlessini (Amlodipine, Perindopril Arginine)

Amlodipine and Perindopril arginine, the active ingredients in Neoamlessini, are a calcium channel blocker and an ACE inhibitor presented as an oral tablet for systemic use. The combination therapy targets two complementary pathways to achieve consistent blood pressure control and reduce cardiovascular risk. They are prescribed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Neoamlessini as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches and reliable logistics for global distribution.

Neoamlessini is indicated for hypertension, a condition characterized by chronically elevated arterial pressure.

- Essential hypertension: reduces both systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: provides consistent control of systolic pressure in older adults. - Hypertension requiring combination therapy: offers dual‑mechanism action to improve blood pressure control when monotherapy is insufficient.

The most frequently reported adverse reactions and the less common but serious events associated with Neoamlessini are listed below.

Common Side Effects: - Headache - Peripheral edema - Flushing - Dizziness

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Liver enzyme elevation

Before initiating Neoamlessini, clinicians should consider the following precautions.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Renal function: evaluate creatinine clearance, especially in patients with renal impairment. - History of angioedema: avoid in individuals with prior ACE‑inhibitor–induced angioedema. - Pregnancy: use only if potential benefit justifies risk, as safety data are limited. - Concomitant potassium‑sparing agents: monitor serum potassium levels. - Store at below 25°C: keep in the original packaging, protect from moisture.

Neoamlessini may interact with other medicines; notable interactions are categorized by their clinical significance.

Major Interactions (Avoid): - Concurrent ACE inhibitors or ARBs: additive risk of hyperkalaemia and renal dysfunction. - Aliskiren in diabetic patients: increased risk of hypotension, renal impairment, and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: may enhance antihypertensive effect leading to hypotension. - Simvastatin or other CYP3A4 substrates: amlodipine can increase plasma concentrations, requiring dose adjustment.